Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
出版年份 2020 全文链接
标题
Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
作者
关键词
-
出版物
Journal of Translational Medicine
Volume 18, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-06-12
DOI
10.1186/s12967-020-02404-x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- New predictors for immunotherapy responses sharpen our view of the tumour microenvironment
- (2020) Tullia C. Bruno NATURE
- Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
- (2020) Qingyang Xiao et al. Journal of Clinical Medicine
- Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
- (2020) Pei-Chang Lee et al. Cancers
- Influence of Body Mass Index on Survival and Prognosis in Squamous Cell Carcinoma of Head and Neck
- (2020) Peng Li et al. Cancer Management and Research
- Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition
- (2019) Girish S. Naik et al. Journal for ImmunoTherapy of Cancer
- A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
- (2019) Alessio Cortellini et al. Journal for ImmunoTherapy of Cancer
- Sub-cutaneous Fat Mass measured on multislice computed tomography of pretreatment PET/CT is a prognostic factor of stage IV non-small cell lung cancer treated by nivolumab
- (2019) Geoffrey Popinat et al. OncoImmunology
- Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
- (2019) Ugo De Giorgi et al. CLINICAL CANCER RESEARCH
- Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer—Beyond the Misdiagnosis
- (2019) Vassiliki Kotoula et al. JAMA Oncology
- Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients
- (2019) Valentina Magri et al. Cancer Management and Research
- MA07.09 Impact of Body Mass Index on Clinical Outcomes of Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer
- (2019) A. Kulkarni et al. Journal of Thoracic Oncology
- BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma
- (2019) Brian W. Labadie et al. Journal of Translational Medicine
- Immune-Related Adverse Events of Immune Checkpoint Inhibitors—From a Clinical to Pathophysiological View
- (2019) Xu Yang et al. JAMA Oncology
- The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer
- (2019) Eiki Ichihara et al. LUNG CANCER
- Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
- (2019) Jianchun Duan et al. JAMA Oncology
- Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non–Small Cell Lung Cancer
- (2019) Ganessan Kichenadasse et al. JAMA Oncology
- Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers
- (2018) Lauriane Chambard et al. BONE
- Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
- (2018) Fabio Conforti et al. LANCET ONCOLOGY
- Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
- (2018) Jennifer L McQuade et al. LANCET ONCOLOGY
- Secretion of autoimmune antibodies in the human subcutaneous adipose tissue
- (2018) Daniela Frasca et al. PLoS One
- Association of baseline body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with nivolumab (N) and pembrolizumab (P).
- (2018) Jizu Zhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
- (2018) Ming Yi et al. Molecular Cancer
- Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study
- (2018) Georg Richtig et al. PLoS One
- Does high body mass index negatively affect the surgical outcome and long-term survival of gastric cancer patients who underwent gastrectomy: A systematic review and meta-analysis
- (2018) Bochao Zhao et al. EJSO
- Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
- (2018) Ziming Wang et al. NATURE MEDICINE
- Cancer immunoediting and resistance to T cell-based immunotherapy
- (2018) Jake S. O’Donnell et al. Nature Reviews Clinical Oncology
- CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
- (2017) Bernard Escudier et al. EUROPEAN UROLOGY
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obesity, Inflammation, and Cancer
- (2016) Tuo Deng et al. Annual Review of Pathology-Mechanisms of Disease
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- The role of body composition evaluation by computerized tomography in determining colorectal cancer treatment outcomes: A systematic review
- (2015) G. Malietzis et al. EJSO
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
- (2010) Andreas Stang EUROPEAN JOURNAL OF EPIDEMIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation